109 related articles for article (PubMed ID: 19663741)
1. ABCB1: the role in Parkinson's disease and pharmacokinetics of antiparkinsonian drugs.
Vautier S; Fernandez C
Expert Opin Drug Metab Toxicol; 2009 Nov; 5(11):1349-58. PubMed ID: 19663741
[TBL] [Abstract][Full Text] [Related]
2. Association of a polymorphism in the ABCB1 gene with Parkinson's disease.
Westerlund M; Belin AC; Anvret A; Håkansson A; Nissbrandt H; Lind C; Sydow O; Olson L; Galter D
Parkinsonism Relat Disord; 2009 Jul; 15(6):422-4. PubMed ID: 19196542
[TBL] [Abstract][Full Text] [Related]
3. Interactions between antiparkinsonian drugs and ABCB1/P-glycoprotein at the blood-brain barrier in a rat brain endothelial cell model.
Vautier S; Milane A; Fernandez C; Buyse M; Chacun H; Farinotti R
Neurosci Lett; 2008 Sep; 442(1):19-23. PubMed ID: 18598736
[TBL] [Abstract][Full Text] [Related]
4. No influence of 3435C>T ABCB1 (MDR1) gene polymorphism on risk of adult acute myeloid leukemia and P-glycoprotein expression in blast cells.
Jamroziak K; Balcerczak E; Cebula B; Janus A; Mirowski M; Robak T
Ther Drug Monit; 2006 Oct; 28(5):707-11. PubMed ID: 17038891
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic implications of the MDR-1 gene.
Mealey KL
J Vet Pharmacol Ther; 2004 Oct; 27(5):257-64. PubMed ID: 15500562
[TBL] [Abstract][Full Text] [Related]
6. MDR1 gene polymorphisms and clinical relevance.
Li YH; Wang YH; Li Y; Yang L
Yi Chuan Xue Bao; 2006 Feb; 33(2):93-104. PubMed ID: 16529292
[TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein activity and biological response.
Vaalburg W; Hendrikse NH; Elsinga PH; Bart J; van Waarde A
Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):257-60. PubMed ID: 16043202
[TBL] [Abstract][Full Text] [Related]
8. Role of integrative pharmacokinetic and pharmacodynamic optimization strategy in the management of Parkinson"s disease patients experiencing motor fluctuations with levodopa.
Okereke CS
J Pharm Pharm Sci; 2002; 5(2):146-61. PubMed ID: 12207867
[TBL] [Abstract][Full Text] [Related]
9. Biliary excretion of technetium-99m-sestamibi in wild-type dogs and in dogs with intrinsic (ABCB1-1Delta mutation) and extrinsic (ketoconazole treated) P-glycoprotein deficiency.
Coelho JC; Tucker R; Mattoon J; Roberts G; Waiting DK; Mealey KL
J Vet Pharmacol Ther; 2009 Oct; 32(5):417-21. PubMed ID: 19754906
[TBL] [Abstract][Full Text] [Related]
10. Potential impact of ABCB1 (p-glycoprotein) polymorphisms on avermectin toxicity in humans.
Macdonald N; Gledhill A
Arch Toxicol; 2007 Aug; 81(8):553-63. PubMed ID: 17354009
[TBL] [Abstract][Full Text] [Related]
11. [Inter- and intraindividual pharmacokinetic variations in the treatment of Parkinson's disease].
Nomoto M; Nakatsuka A; Nagai M; Yabe H; Moritoyo T; Moritoyo H; Nisikawa N
Rinsho Shinkeigaku; 2005 Nov; 45(11):895-8. PubMed ID: 16447756
[TBL] [Abstract][Full Text] [Related]
12. P-glycoprotein and pharmacokinetics.
Levêque D; Jehl F
Anticancer Res; 1995; 15(2):331-6. PubMed ID: 7763002
[TBL] [Abstract][Full Text] [Related]
13. The anti-Parkinson drug budipine is exported actively out of the brain by P-glycoprotein in mice.
Uhr M; Ebinger M; Rosenhagen MC; Grauer MT
Neurosci Lett; 2005 Jul 22-29; 383(1-2):73-6. PubMed ID: 15936515
[TBL] [Abstract][Full Text] [Related]
14. Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation.
Sun M; Kingdom J; Baczyk D; Lye SJ; Matthews SG; Gibb W
Placenta; 2006; 27(6-7):602-9. PubMed ID: 16143395
[TBL] [Abstract][Full Text] [Related]
15. Canine ABCB1 and macrocyclic lactones: heartworm prevention and pharmacogenetics.
Mealey KL
Vet Parasitol; 2008 Dec; 158(3):215-22. PubMed ID: 18922637
[TBL] [Abstract][Full Text] [Related]
16. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease.
Droździk M; Białecka M; Myśliwiec K; Honczarenko K; Stankiewicz J; Sych Z
Pharmacogenetics; 2003 May; 13(5):259-63. PubMed ID: 12724617
[TBL] [Abstract][Full Text] [Related]
17. Inter- and intra-individual variation in L-dopa pharmacokinetics in the treatment of Parkinson's disease.
Nomoto M; Nishikawa N; Nagai M; Yabe H; Nakatsuka A; Moritoyo H; Moritoyo T; Kubo M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S21-4. PubMed ID: 19131037
[TBL] [Abstract][Full Text] [Related]
18. Influence of adenosine triphosphate and ABCB1 (MDR1) genotype on the P-glycoprotein-dependent transfer of saquinavir in the dually perfused human placenta.
Rahi M; Heikkinen T; Hakkola J; Hakala K; Wallerman O; Wadelius M; Wadelius C; Laine K
Hum Exp Toxicol; 2008 Jan; 27(1):65-71. PubMed ID: 18480151
[TBL] [Abstract][Full Text] [Related]
19. Emerging significance of P-glycoprotein in understanding drug disposition and drug interactions in psychopharmacology.
Carson SW; Ousmanou AD; Hoyler SL
Psychopharmacol Bull; 2002; 36(1):67-81. PubMed ID: 12397848
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective therapy for Parkinson's disease.
Koller WC
Exp Neurol; 1997 Mar; 144(1):24-8. PubMed ID: 9126147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
